ADARx Pharmaceuticals, Inc.

ADARx Pharmaceuticals, Inc.

ADRX - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$1.37B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
ADARx Pharmaceuticals, Inc.ADARx Pharmaceuticals, Inc.-5.8--17%--
$35.00

Target Price by Analysts

173.7% upsideADARx Pharmaceuticals Target Price DetailsTarget Price
$0.94

Current Fair Value

92.6% downside

Overvalued by 92.6% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$1.37 Billion
Enterprise Value$828.58 Million
Earnings per Share$-0.97
Beta0
Outstanding Shares107,255,963

Return

Return on Equity-16.76%ROE
Return on Assets-10.36%
Return on Invested Capital-12.85%

Valuation & Multiples

P/E Ratio-5.77P/E Ratio
PEG-PEG
Price to Sales-Price to Sales
Price to Book Ratio2.56Price to Book Ratio
Enterprise Value to Revenue123.24
Enterprise Value to EBIT-7.28
Enterprise Value to Net Income-9
Total Debt to Enterprise0.03
Debt to Equity0.05Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 12, 2026
EPS
-$1.74
Est. -$0.40
Revenue
$2.20 M
Est. $2.58 M

Institutional Put/Call Ratio

Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.

Put/Call Ratio0.00000%
Total Calls-
Total Puts-

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %71.57%▲ 71.57%
Total Invested$1.53B
Investors Holding62▲ 62.00%

About ADARx Pharmaceuticals, Inc.

100 employees
CEO: Zhen Li

ADARx Pharmaceuticals, Inc. is a late-clinical-stage biotechnology company. It focuses on developing next-generation small interfering RNA (siRNA) therapeutics for diseases with significant unmet medical needs. The company was founded by...

ADARx Pharmaceuticals Insider Information FAQ

Stockcircle tracks 2 top investors with a current 13F position in ADARx Pharmaceuticals. Holdings come from the latest quarterly 13F filings filed with the SEC.

In the latest 13F quarter on Stockcircle, 2 top investors increased or opened positions among tracked top investors. Changes are based on reported share counts in their quarterly filings, not day-to-day trading.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.